Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types.This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required.While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.

2nd Department of Pediatrics Semmelweis University Budapest Hungary

Antwerp University Hospital Edegem Belgium

Central European Institute of Technology Masaryk University Brno Czech Republic

Computer Science Department University of Massachusetts Amherst MA USA

CSTS Health Care® Toronto Canada

Department of Cell Molecular and Developmental Biology Sackler School of Graduate Biomedical Sciences Tufts University Boston MA USA

Department of Paediatric Oncology University Hospital Brno Brno Czech Republic

Department of Pathology Tufts Medical Center Boston MA USA

Department of Pathology University Hospital Brno Brno Czech Republic

Department of Pediatric Hematology and Oncology AP HM Marseille France

Department of Pediatric Hematology Oncology Floating Hospital for Children at Tufts Medical Center Boston MA USA

Department of Pediatric Hematology Oncology Institute of Pediatrics Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Pediatric Oncology Comenius University Bratislava Slovakia

Department of Pediatric Oncology Emma Children Hospital Academic Medical Centre University of Amsterdam Amsterdam The Netherlands

Department of Pediatric Surgery University Hospital Brno Brno Czech Republic

Department of Pediatrics Medical University of Vienna Vienna Austria

Faculty of Medicine Masaryk University Brno Czech Republic

ICRC St Anna University Hospital Brno Brno Czech Republic

Regional Center for Applied Molecular Biology RECAMO Brno Czech Republic

Specialized Children's Oncohematology Hospital Sofia Bulgaria

UMR S_911 CRO2 Aix Marseille Université Marseille France

Zobrazit více v PubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. PubMed

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. PubMed

Egas-Bejar D, Anderson PM, Agarwal R, Corrales-Medina F, Devarajan E, Huh WW, Brown RE, Subbiah V. Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience. 2014;1:167–179. doi: 10.18632/oncoscience.21. PubMed DOI PMC

Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, Solomon E, Carritt B, Bodmer WF. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature. 1982;299:747–749. PubMed

Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005. PubMed PMC

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome research. 2012;22:196–207. PubMed PMC

Tannock IF. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. European urology. 2014;65:846–847. PubMed

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012;366:883–892. PubMed PMC

de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–549. PubMed

Collins FS, Varmus H. A new initiative on precision medicine. The New England journal of medicine. 2015;372:793–795. PubMed PMC

Council NR. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press; 2011. PubMed

Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of clinical oncology. 2015 PubMed PMC

Saret CJ, Winn AN, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015;125:1866–1869. PubMed PMC

Gladwell M. The Treatment: Why is it so difficult to develop drugs for cancer? The New Yorker: Conde Nast; 2010. PubMed

Skipper HE, Schabel FM, Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431–450. PubMed

Skipper HE, Schabel FM, Jr, Lloyd HH. Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin Hematol. 1978;15:207–219. PubMed

Schabel FM, Jr., Skipper HE, Trader MW, Laster WR, Jr., Corbett TH, Griswold DP., Jr. Concepts for controlling drug-resistant tumor cells. Eur J Cancer. 1980;(Suppl 1):199–211. PubMed

Andre N, Pasquier E. For cancer, seek and destroy or live and let live? Nature. 2009;460:324. PubMed

Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, Zitterbart K, Kadlecova V, Mazanek P. Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study. Onkologie. 2006;29:308–313. PubMed

Zapletalova D, Andre N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82:249–260. PubMed

Andre N, Pasquier E, Kamen B. Can targeted therapy be successful without metronomic scheduling? Current topics in medicinal chemistry. 2012;12:1639–1642. PubMed

Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nature reviews Clinical oncology. 2014;11:413–431. PubMed

Komeili-Movahhed T, Fouladdel S, Barzegar E, Atashpour S, Hossein Ghahremani M, Nasser Ostad S, Madjd Z, Azizi E. PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy. Iranian journal of basic medical sciences. 2015;18:472–477. PubMed PMC

Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochemical and biophysical research communications. 2014;444:670–675. PubMed

Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392–400. PubMed

Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose-response. 2009;8:253–284. PubMed PMC

Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726–2734. PubMed

Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno RK, Duggan MA, Pfeiffer RM, Ooshima A, Cornelison R, Gierach GL, Brinton LA, Lissowska J, Peplonska B, Wakefield LM, Sherman ME. Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat. 2010;121:727–735. PubMed PMC

Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clinical cancer research. 2002;8:221–232. PubMed

Bautista F, Di Giannatale A, Dias-Gastellier N, Fahd M, Valteau-Couanet D, Couanet D, Grill J, Brugieres L, Dufour C, Gaspar N, Minard-Colin V, Kalifa C, Oberlin O, Patte C, Vassal G, Geoerger B. Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience. Journal of pediatric hematology/oncology. 2015;37:e102–110. PubMed

Abrams J, Conley B, Mooney M, Zwiebel J, Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, Williams M, Staudt L, Doroshow J. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2014:71–76. PubMed

Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. The AAPS journal. 2012;14:781–791. PubMed PMC

Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing—time for a change? Nature reviews Clinical oncology. 2011;8:439–444. PubMed

Rodriguez FJ, Lim KS, Bowers D, Eberhart CG. Pathological and molecular advances in pediatric low-grade astrocytoma. Annual review of pathology. 2013;8:361–379. PubMed PMC

Hu P, Bader G, Wigle DA, Emili A. Computational prediction of cancer-gene function. Nature reviews Cancer. 2007;7:23–34. PubMed

Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nature genetics. 2013;45:1113–1120. PubMed PMC

Devarakonda S, Morgensztern D, Govindan R. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma. Oncology. 2013;27:899–906. PubMed

Gonda DD, Cheung VJ, Muller KA, Goyal A, Carter BS, Chen CC. The Cancer Genome Atlas expression profiles of low-grade gliomas. Neurosurgical focus. 2014;36:E23. PubMed

Ma CX, Ellis MJ. The Cancer Genome Atlas: clinical applications for breast cancer. Oncology. 2013;27:1263–1269. 1274-1269. PubMed

Rietman EA, Colt JZ, Tuszynski JA. Interactomes, manufacturomes and relational biology: analogies between systems biology and manufacturing systems. Theoretical biology & medical modelling. 2011;8:19. PubMed PMC

Rietman EA, Karp RL, Tuszynski JA. Review and application of group theory to molecular systems biology. Theoretical biology & medical modelling. 2011;8:21. PubMed PMC

Benzekry S, Tuszynski JA, Rietman EA, Lakka Klement G. Design principles for cancer therapy guided by changes in complexity of protein-protein interaction networks. Biol Direct. 2015;10:32. PubMed PMC

Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:9209–9212. PubMed PMC

Leiserson MD, Vandin F, Wu HT, Dobson JR, Eldridge JV, Thomas JL, Papoutsaki A, Kim Y, Niu B, McLellan M, Lawrence MS, Gonzalez-Perez A, Tamborero D, Cheng Y, Ryslik GA, Lopez-Bigas N, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature genetics. 2015;47:106–114. PubMed PMC

Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A, Kolas N, O'Donnell L, Reguly T, Nixon J, Ramage L, Winter A, Sellam A, Chang C, et al. The BioGRID interaction database: 2015 update. Nucleic acids research. 2015;43:D470–478. PubMed PMC

Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic acids research. 2006;34:D535–539. PubMed PMC

Boukerroucha M, Josse C, Segers K, El-Guendi S, Freres P, Jerusalem G, Bours V. BRCA1 germline mutation and glioblastoma development: report of cases. BMC cancer. 2015;15:181. PubMed PMC

Yang W, Yang X, David G, Dorsey JF. Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells. Cancer biology & therapy. 2012;13:1339–1348. PubMed PMC

Vespignani A. Modelling dynamical processes in complex socio-technical systems. Nature physics. 2012;8:32–39.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929–944. PubMed PMC

Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology. 2015 PubMed

Le Tourneau C, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Targeted oncology. 2012;7:253–265. PubMed

Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. British journal of cancer. 2014;111:17–24. PubMed PMC

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507–2516. PubMed PMC

Young K, Minchom A, Larkin J. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future oncology. 2012;8:499–507. PubMed

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–972. PubMed PMC

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118–122. PubMed

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977. PubMed PMC

Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. The Journal of experimental medicine. 2006;203:1651–1656. PubMed PMC

Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology. 2013;2:e24320. PubMed PMC

Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer biology & medicine. 2014;11:237–246. PubMed PMC

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014;371:2189–2199. PubMed PMC

Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, Burke MM, Ralabate AL, Rivera AL, Kronenberg SA, Agunwamba B, Feely W, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) ASCO Meeting Abstracts. 2014;32(15_suppl):LBA9003.

Giovannetti E, Codacci-Pisanelli G, Peters GJ. TFAP2E-DKK4 and chemoresistance in colorectal cancer. The New England journal of medicine. 2012;366:966. author reply 966. PubMed

Ebert MP, Tanzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Rocken C, Keller G, Langer R, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. The New England journal of medicine. 2012;366:44–53. PubMed

Afranie-Sakyi JA, Klement GL. The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics. Cancer letters. 2015;357:1–7. PubMed PMC

Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–4293. PubMed

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. The Journal of clinical investigation. 2000;105:R15–24. PubMed PMC

Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. The Journal of clinical investigation. 2000;105:1045–1047. PubMed PMC

Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Annals of oncology. 2002;13:12–15. PubMed

Kerbel RS, Viloria-Petit A, Klement G, Rak J. ‘Accidental’ anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European journal of cancer. 2000;36:1248–1257. PubMed

Andre N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, Gentet JC, Verschuur A. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2011;2:960–965. doi: 10.18632/oncotarget.358. PubMed DOI PMC

Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–465. PubMed

Andre N, Padovani L, Pasquier E. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol. 2011;7:385–394. PubMed

Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer letters. 2015;358:100–106. PubMed PMC

Hafner CR, Albrecht Vogt, Thomas New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPAR Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy. Current Cancer Drug Targets. 2005;5:393–419. PubMed

Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–436. PubMed

Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–1886. PubMed

Ghirighelli F, Menard C, Puig PE, Ladoire s, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2007;56:641–648. PubMed PMC

Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 2012;72:1103–1115. PubMed PMC

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239. PubMed PMC

Ebos JM. Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis. Cancer research. 2015;75:3427–3435. PubMed

Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best practice & research Clinical endocrinology & metabolism. 2010;24:439–449. PubMed PMC

Klement GL. Eco-evolution of cancer resistance. Sci Transl Med. 2016;8:327fs325. PubMed

Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize

Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai